Dr. Axel Johann, Promega, Mannheim, Germany
Traditional ADCC bioassays suffer from donor primary NK effector cell variability that can complicate interpretation of Fcgamma RIIIa variant-specific ADCC efficiencies in such comparisons. At Promega we have focused on developing high performance bioassays that ease transferability to QC lot release and stability bioassays. Our ADCC bioassays are bioluminescence-based, simple, and homogeneous. Cells in bioassay kits are ‘cell reagents’, in frozen, thaw-and-use format and ready for immediate use in the bioassay and thereby reducing assay variability to an minimum. ADCC Reporter Bioassays (V158 and F158 versions) are optimal surrogates for classic cytolytic ADCC bioassays.